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ABSTRACT  The  response of human  endothelial  cell  migration  to various  extracellular  matrix 
components  and  growth  factors  has  been  assessed.  Human  endothelial  cells  demonstrate 
increased  chemotaxis  and  chemokinesis  when  placed  in  a  modified  Boyden chamber with 
endothelial cell growth factor (ECGF) used at a concentration of 10  -9 M. Anti-ECGF antibody 
inhibits the chemotactic  response. Heparin (10  -a to  10  -l° M) was also chemotactic and was 
shown  to  potentiate  the  chemotactic  activity  of  ECGF. Although  laminin,  fibronectin,  the 
polypeptide (epidermal, fibroblast, and nerve) growth factors, and collagen types I,  II,  Iit,  IV, 
and V  demonstrate a chemotactic  response, these activities  were one third to one half less 
than observed with  ECGF. These data suggest that ECGF and heparin  may  play a significant 
role  as  response  modifiers  of  human  endothelial  cell  migration  which  may  be  relevant  to 
tumor metastasis,  wound healing, and atherogenesis. 
Chemotactic behavior is a property of a variety of cell types 
engaged  in  biological  processes  including  inflammation, 
wound  repair,  organ  development,  neurite  outgrowth,  and 
tumor invasion (29). Factors that modify cellular chemotaxis 
are  also  important  as  modulators  of  cellular  growth  and 
differentiation ( 17, 26, 28).' Extracellular matrix proteins such 
as  fibronectin  and  laminin  have  been  shown  to  stimulate 
mammalian cell motility in a variety of cell types (1, 25, 28, 
39) 2 and may play a prominent role in the process of differ- 
entiation  (1,  3,  12,  15,  16,  22,  27,  36,  40,  41). 1 Endothelial 
cell growth factor (ECGF) 3, the principle polypeptide mitogen 
for human endothelial cells in vitro (20), has been implicated 
in neovascularization (19,  30). In addition,  it has been dem- 
onstrated that the glycosaminoglycan, heparin, is a modulator 
of the biological activity of ECGF (30, 37). Specifically, hep- 
arin  increases the  activity  of the  polypeptide  mitogen by a 
mechanism  involving ECGF  receptor occupancy (30).  Fur- 
thermore,  mast  cell  heparin  has  been  shown  to  stimulate 
migration of bovine capillary endothelial cells but not endo- 
thelium from bovine aorta (4). Since heparin in combination 
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with ECGF promotes cell growth (20,  30,  37) and mediates 
alterations  in endothelial  cell phenotype (37), we examined 
their chemotactic properties. We report here that ECGF and 
heparin  are  indeed  chemotactic  for human  umbilical  vein 
endothelial cells. 
MATERIALS  AND  METHODS 
Human Endothelial Cell Cultures:  Human  endothelial  cells de- 
rived from the umbilical vein were propagated as previously described (21). In 
all cases, early passage cells were used (equal to or less than 25 cumulative 
population doublings). The cells used for the chemotaxis assays were removed 
from the cell culture dishes by incubation in a divalent, cation-free, balanced 
salt solution containing 0.1% EDTA, 0.1% EGTA in 25 mM Hepes,  l0 mM 
Na2 HCO3, 6 mM K2HPO4,  100 mM NaCl and 60 mM mannitol, pH 7.4. 
Chemotaxis Assay:  Chemotaxis was assayed in the modified Boyden 
chamber as previously described (29).  Briefly, human  endothelial cells were 
suspended at a concentration of 2.5 x  l05 cells/ml in Medium 199 containing 
200 ug/ml bovine serum albumin and placed in the upper compartment of the 
Boyden chamber. The lower compartment, which contained the chemoattract- 
ant, was separated from the upper compartment by a  nuclepore filter (Neuro 
Probe, Inc., Cabin John, MD; pore diameter, 8 urn). After a 4-h incubation at 
37°C, filters were removed, washed, stained with hematoxylin, and mounted 
bottom side up on glass slides. Ten high power fields (× 400) were counted to 
determine the number of cells that had migrated entirely across the  100-urn 
width oftbe filter. Negative controls were the number of cells that had migrated 
in the absence of an attractant, in all cases, the SEM did not exceed 10%. 
Preparation  of 5ubstrates and Antibodies:  Type  I collagen was 
prepared from lathyritic  rat skin (5); type lI collagen from a rat chondrosarcoma 
(35); type llI collagen from fetal calf skin (9); type IV collagen from the EHS 
tumor ( 18); and type V collagen from human placenta (6). ECGF was prepared 
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pH in  a  low ionic  strength  buffer.  The extract  was next  subjected  to acid 
extraction  and  a  series of ammonium sulfate  precipitations.  The  resulting 
material  was further  purified  by heparin-Sepharose  affinity chromatography 
followed by  reversed-phase  high  performance  liquid  chromatography.  This 
material  yields a single band on SDS PAGE, a single UV absorbing peak on 
reversed-phase high performance  liquid  chromatography,  and a  single NH2- 
terminal  residue as determined  by automated Edman degradation.  Laminin 
and fibronectin were purified as previously described (14, 18, 38), and antibod- 
ies to laminin  and fibronectin  were raised  in rabbits (10). Their specificities 
were confirmed by immunoprecipitation  and Western blot analysis. Antibody 
to purified ECGF was prepared as previously described (20). The polypeptide 
(epidermal, fibroblast, and nerve) growth factors were purchased from Collab- 
orative  Research,  Inc.  (Lexington,  MA). Insulin  was obtained  from Sigma 
Chemical Co. (St. Louis, MO). Heparin  was obtained  from Armour Pharma- 
ceutical Co. (Kankehee, IL). 
RESULTS 
ECGF is a Chemoattractant  for 
Human Endothelial Cells 
When  human  endothelial  cells were placed in the  upper 
compartment of a modified Boyden chamber at a density of 
2 x  l0  s cells per chamber (42), we observed that ECGF and 
heparin, alone or in combination, stimulated human endo- 
thelial cell migration (Fig.  1). The optimal concentration of 
ECGF for directed cell movement was  10  -9 M. Heparin also 
stimulated human endothelial cell migration at  10  -9 M. The 
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TABLE  I.  Chemotactic Response of Human Endothelial Cells to 
Biological Response Modifiers 
Polypeptide or  Number of cells/high power field 
Glycoprotein 
I0 -~° M  10 -9 M  I0 -8 M 
BSA  12+5  12  +2  10+4 
EGF  20 _  4  24 ___ 3  20 4- 5 
FGF  13+5  15___5  14+5 
NGF  11 ___ 3  12 _  3  13 4- 6 
Insulin  10 4- 2  10 4- 1  8 +  2 
Collagen I  18 +  4  19 __- 2  22 +  3 
Collagen II  12 __. 4  13 __. 3  11  +  4 
Collagen Ill  25 4- 6  29 4- 4  20 4- 4 
Collagen IV  25 4- 5  21  +  3  22 4- 5 
Collagen V  25 4- 6  27 +  5  18 4- 5 
Laminin  20 4- 4  22 4- 4  25 _  5 
Fibronectin  21  4- 5  23 4- 4  28 4- 6 
Chemotactic  assays were performed in triplicate  as described  in  Materials 
and  8  Methods. All factors were examined at concentrations between 10-  and 
10  -1° M. 
response of the cells (Fig.  1) relative to either the heparin or 
ECGF response. Although laminin and fibronectin stimulated 
endothelial cell migration at 10  -9 M, this response was only 
30 to 40% of the chemotactic response observed with ECGF 
and  heparin  at  10  -9  M  (Table  I).  In  some  cases  ECGF, 
heparin, and collagen types III, IV, and V at increased con- 
centrations revealed a decline in chemotaxis (Table I, Fig.  I). 
This decrease in response to higher concentrations of chem- 
oattractants is commonly observed in assays of this type and 
is generally ascribed to either receptor desensitization or the 
possibility of a gradient breakdown (29). 
The concentration of ECGF in the upper and lower wells 
of the Boyden chamber was varied in a systematic fashion to 
distinguish chemotaxis from chemokinesis and also to distin- 
guish positive from negative chemotaxis (42).  We observed 
an  increase  in  endothelial  cell  chemokinetic  motility as a 
function  of the  concentration  of ECGF  (Fig.  2).  We  also 
observed a substantial chemotactic activity. The number of 
cells that had migrated in positive gradients was substantially 
greater than those that migrated in negative gradients. These 
data  demonstrate  that  ECGF  induces  a  true  chemotactic 
response in human endothelial cells.  An additional checker- 
board assay was performed using heparin as the chemoattract- 
ant. In this experiment we observed positive chemotaxis and 
positive chemokinesis. No movement of human endothelial 
cells was noted when a negative gradient was established (Fig. 
3). 
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FIGURE  1  Chemotactic  response of  human  endothelial  cells  to 
ECGF and heparin. Chemotaxis was assayed in the modified Boy- 
den chamber. After a 4-h incubation at 37°C in a 100% humidified 
chamber  containing  5%  CO2,  the  filters were  removed,  fixed  in 
100% methanol, and stained with  hematoxylin and eosin. Because 
of the heterogeneous nature of heparin preparations, we assumed 
an average molecular mass of 2 x  104 daltons. Molar concentrations 
for heparin are based on this assumption. The data are expressed 
as the average number of migrated cells per high  power field  (x 
400) +  one standard deviation. Each assay was performed in tripli- 
cate. The number of migrated cells per filter did not differ by more 
than 10%. 
Antibodies Against ECGF Inhibit 
ECGF-induced Chemotaxis 
Human endothelial cells treated with an antibody directed 
against ECGF, which inhibits ECGF-induced endothelial cell 
proliferation  and  ECGF  receptor  occupancy  (20),  showed 
marked  inhibition  of the  chemotactic  response  to  ECGF. 
Antibodies against laminin (data not shown) or fibronectin 
had no effect on ECGF-induced human endothelial cell mi- 
gration (Fig. 4).  In a  series of separate experiments, human 
endothelial cells were assayed for their chemotactic response 
to the various antibodies. We observed no movement of cells 
to either anti-ECGF, anti-laminin, or anti-fibronectin in the 
absence of ECGF (Fig. 5). In addition, when ECGF was added 
to the lower compartment, a maximal response was observed 
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FIGURE  3  Checkerboard analysis of the motile response of human  ANTIBODY  DILUTION 
endothelial cells to heparin. Chemotaxis assays are performed as 
described in Materials and Methods.  Each assay was performed in 
triplicate.  Numbers within  the  inner  box express the  number of 
migrated cells per high power field (x 400). Heparin concentrations 
are varied as indicated. The response of human endothelial cells to 
the absence of a gradient (chemokinesis) are shown on the diagonal 
and  to  a  negative  gradient  above  the  diagonal.  Response  to  a 
positive gradient (chemotaxis) is shown below the diagonal. 
(Fig.  5).  Furthermore,  anti-ECGF antibody did  not  inhibit 
endothelial  cell  movement to either laminin  or fibronectin 
(data not shown). These studies demonstrate the specificity of 
ECGF-induced endothelial cell migration and further suggest 
that the inhibition of cell motility by anti-ECGF was not due 
to a nonspecific antibody interaction with human endothelial 
cells. 
Chemotactic  Activity of Other Biological 
Response Modifiers on Human Endothelial Cells 
Additional factors which, in general, modulate mammalian 
cell proliferation and differentiation were examined for their 
FIGURE  4  Inhibition of ECGF-induced endothelial cell chemotaxis. 
Chemotactic  response  of  human  endothelial  cells  to  ECGF  was 
measured in the  presence and absence of antibodies. Anti-fibro- 
nectin (initial concentration of  100 ~g/ml protein) and anti-ECGF 
(initial concentration of 100 #g/ml protein (20) were incubated with 
human endothelial cells in the upper compartment of the Boyden 
chamber. ECGF (10  -9 M) was used as the chemoattractant in the 
lower well  of the  Boyden  chamber.  The  chemotaxis  assay  was 
performed as described in Materials and Methods. 
chemotactic activity with human endothelial cells.  These in- 
cluded  epidermal  growth  factor,  basic  pI-fibroblast growth 
factor, nerve growth factor, insulin, and collagen types I, II, 
III, IV, and V.  The various factors were examined for che- 
motaetic activity in the modified Boyden chamber at concen- 
trations of 10  -8,  10 -9,  and  10  -l° M; the results obtained are 
shown in Table I. Collagen types I, III, IV, and V  and EGF 
were capable of stimulating one third to one half maximal 
stimulatory capacity as compared to ECGF. Collagen type II 
was without effect in chemotactic stimulation. Both fibroblast 
and nerve growth factor were also without effect. These data 
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ANTIBODY  DILUTION 
Antibodies against fibronectin,  laminin,  and  ECGF  are 
not  chemotactic  for  human  endothelial  cells.  The  chemotactic 
response of human endothelial cells to anti-fibronectin, anti-lami- 
nin,  and  anti-ECGF  (all  initial  protein  concentrations  adjusted to 
100 ~.g/ml  protein) was measured. Anti-laminin  plus ECGF at  10  -9 
M  was additionally tested. Assays were performed as described in 
Materials and Methods. All assays were performed in triplicate. 
TABLE II.  Chemotactic Response of Human Endothelial Cells  to 
Various  Biological Response  Modifiers with and without 10 -9 M 
Heparin 
Number of cells/high power field 
Polypeptide or 
Glycoprotein  +  Heparin  -  Heparin 
EGF  26 -  3  25 +  4 
FGF  14 +  3  14 +  4 
Laminin  25 +  3  22 +  2 
Fibronectin  25 +  2  23 _+ 3 
Endothelial cell chemotaxis was assayed  using 10  -9 M polypeptide or glyco- 
protein  with  and without the addition  of 10  -9 M  heparin. Results are the 
mean of four experiments plus and minus one standard deviation. 
demonstrate that ECGF is a more potent chemoattractant for 
human  endothelial  cells  in  vitro  relative  to  other  known 
chemoattractants. In addition, we tested the ability ofheparin 
in  combination  with  epidermal  growth  factor,  fibroblast 
growth factor, laminin, and fibronectin to stimulate directed 
movement of endothelial cells. We observed no increase (or 
decrease) in chemotactic responsiveness when heparin (at 10  -9 
M) was included (Table II). 
involve heparin-induced changes in the conformation of the 
polypeptide mitogen (30). The demonstration of heparin and 
ECGF as chemoattractants for endothelial  cells further ex- 
tends these observations and suggests that these components 
may be important in the development of blood vessels. 
Other biological response modifiers have been shown to be 
chemotactic for various cell types. For example, the extracel- 
lular  matrix  glycoproteins,  laminin  and  fibronectin,  are 
known chemoattractants. Murine melanoma cells,  Schwan- 
noma cells, and neutrophils will move towards laminin (24, 
25,  34), 2 while fibronectin stimulates directed  migration of 
Schwann cells, endothelial cells, fibroblasts, and certain tumor 
cells (8,  11, 24,  33,  39, 41).  Furthermore, fibroblasts as well 
as smooth muscle cells move to platelet-derived growth factor 
(13,  32).  In  addition  to  eliciting  a  chemotactic  response, 
platelet-derived growth factor is well recognized as a potent 
stimulator of mesenchymal cell proliferation (3 !). Addition- 
ally, mast cell heparin has been shown to stimulate random 
movement of bovine capillary endothelium (4). In these stud- 
ies, bovine aortic endothelium did not move to any factors. 
Endothelial cells are capable of organization which results 
in the formation of three-dimensional tubular structures in 
vitro (19). The generation of the differentiated endothelial cell 
phenotype in vitro can be accelerated by extracellular matrix 
components (19,  23), and involves endothelial cell migration 
during the early stage of the organizational process (15,  22, 
30). Since extracellular cell culture environments which limit 
endothelial cell proliferation augment the process of endothe- 
lial cell differentiation (15, 22, 23,  30), it is not clear whether 
the chemotactic properties of ECGF participate in the orga- 
nizational  pathway in  vitro.  However,  Senior et  al.,  have 
demonstrated that the chemotactic and proliferative attributes 
of platelet-derived growth factor can be separated (31). There- 
fore, we suggest that the chemotactic and proliferative prop- 
erties of ECGF may also be distinct. 
Neovascularization, which occurs during wound healing as 
well as in tumor growth, is initiated by a variety of biological 
effectors which cause the induction of endothelial cell migra- 
tion (19,  22).  This multitude of diverse biochemical stimuli 
reveals an apparent generalized, rather than specific, response 
of the endothelial cell and supports a model for angiogenesis 
which assumes a number of points of entry and control (19). 
This is especially evident from the chemotactic activity noted 
for many of the biological response modifiers (Table I) which 
would be localized at sites of endothelial cell migration. Our 
data suggest  that ECGF and heparin play a  specific role in 
the  control  of human  endothelial  cell  migration  and  may 
ultimately be involved in the cascade of biochemical events 
which control neovascularization. 
DISCUSSION 
These data demonstrate that human endothelial cells exhibit 
a chemotactic response to both ECGF and heparin. Since the 
chemotactic activity of ECGF is potentiated by heparin  at 
suboptimal concentrations, these data suggest an interaction 
between  the  polypeptide  and  the  glycosaminoglycan. This 
proposed interaction is consistent with the ability of heparin 
to bind ECGF (20) and modulate the mitogen activity of the 
polypeptide (30, 37). Previous studies have demonstrated that 
the modulation by heparin occurs at the receptor level (30). 
The  interaction  between  ECGF  and  heparin  increases  the 
dissociation constant for ECGF receptor occupancy and may 
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